- Home
- RYOJ vs TVRD Comparison
RYOJ vs TVRD Comparison
Compare RYOJ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | TVRD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Japan | United States |
| Employees | N/A | 12 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 35.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RYOJ | TVRD |
|---|---|---|
| Price | $4.20 | $3.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 628.1K | ★ 6.5M |
| Earning Date | 12-15-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $1.50 |
| 52 Week High | $11.43 | $43.65 |
Technical Indicators
Market Signals| Indicator | RYOJ | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 51.64 |
| Support Level | $1.97 | $2.83 |
| Resistance Level | $6.49 | $4.34 |
| Average True Range (ATR) | 0.67 | 0.73 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 83.08 | 37.23 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.